What is the recommended terlipressin dosing regimen for hepatorenal syndrome-associated acute kidney injury?

Terlipressin Dosing for HRS-AKI

Start terlipressin at 1 mg IV every 6 hours (administered as bolus through a peripheral line), and increase to 2 mg every 6 hours on day 4 if serum creatinine fails to decrease by at least 30%. 1, 2

Initial Dosing Strategy

• Starting dose: 1 mg IV bolus every 6 hours (total 4 mg/day) 1, 2
• Route: Peripheral IV line—no central line or ICU monitoring required 1
• Dose escalation: Increase to 2 mg every 6 hours (total 8 mg/day) on day 4 if creatinine reduction is <30% from baseline 1
• Duration: Continue for up to 14 days, or discontinue 24 hours after serum creatinine decreases to <1.5 mg/dL 1, 3

Alternative Continuous Infusion Approach

Continuous infusion may be preferred over bolus dosing due to lower adverse event rates with similar efficacy. 1, 4

• Starting dose: 2 mg/day as continuous IV infusion 1, 3
• Dose escalation: Increase every 24-48 hours up to 12 mg/day until creatinine decreases 3
• Evidence: Trials comparing continuous infusion versus bolus dosing found lower complication rates with continuous infusion while maintaining similar efficacy 1, 4
• Caveat: Continuous infusion is not FDA-approved in the United States; the approved regimen is intermittent bolus dosing 1, 4

Concomitant Albumin Administration

Always administer albumin with terlipressin, but use judiciously to avoid volume overload. 1, 3

• Day 1: 1 g/kg body weight 3
• Subsequent days: 40-50 g/day (or 20-40 g/day per some protocols) 1, 3
• Duration: Continue albumin throughout terlipressin therapy, but reassess volume status frequently 1
• Critical consideration: Excessive albumin increases risk of respiratory failure—use point-of-care ultrasound to guide volume management when possible 1, 5

Contraindications and High-Risk Scenarios

Do not use terlipressin in patients with serum creatinine >5 mg/dL, ACLF grade 3, SpO2 <90%, or active ischemic disease. 1, 6

Absolute Contraindications:

• Active coronary, peripheral, or mesenteric ischemia 1
• SpO2 <90% or significant hypoxemia 1
• Known significant vascular disease 1, 2

Relative Contraindications (Risk May Outweigh Benefit):

• Serum creatinine >5 mg/dL—unlikely to benefit 1, 6
• ACLF grade 3 (≥3 organ failures)—increased risk of respiratory failure 1, 6
• MELD score ≥35 in transplant-listed patients 1
• Acute tubular necrosis (ATN) phenotype—response rate only 29% versus 51% in HRS-AKI 7

Monitoring Requirements

Monitor vital signs including pulse oximetry every 2-4 hours during treatment. 1

• The FDA label recommends continuous pulse oximetry, but this is not routinely done in countries with long-standing terlipressin use 1, 2
• Actively monitor for ischemic complications (abdominal pain, digital ischemia, chest pain) 3
• Watch for respiratory failure development—occurs in 14% of terlipressin-treated patients versus 5% with placebo 1, 8
• Assess volume status frequently, particularly in patients with cirrhotic cardiomyopathy (present in 26% of HRS-AKI patients who develop pulmonary edema) 5

Expected Outcomes

Complete HRS reversal occurs in approximately 32-43% of appropriately selected patients. 8, 6

• HRS reversal rate: 32% with terlipressin versus 17% with placebo in the CONFIRM trial 8
• In patients without ACLF grade 3 or creatinine ≥5 mg/dL, reversal rate improves to 43% 6
• Terlipressin reduces need for renal replacement therapy but does not improve mortality 1, 8
• Chronic kidney disease does not adversely affect treatment response 9

Common Pitfalls

• Excessive albumin administration: Trend toward higher albumin volumes in patients who developed respiratory failure—avoid aggressive volume expansion 1
• Using terlipressin in ATN: Response rate is significantly lower (29%) compared to true HRS-AKI (51%), and risks may outweigh benefits 7
• Continuing therapy beyond 4 days without response: If creatinine remains at or above pretreatment level after 4 days at maximum tolerated dose, discontinue therapy 3
• Ignoring cirrhotic cardiomyopathy: Patients with E/e' ratio >12.5 or tissue Doppler mitral velocity <7 cm/s have poor terlipressin response and higher mortality risk 5